Update on scleroderma-associated interstitial lung disease

Current Opinion in Rheumatology

Volumn 26, Issue 6, 2014, Pages 630-636

  Fan, Ming Hui ^a   Feghali Bostwick, Carol A ^b   Silver, Richard M ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Autoimmune; Connective tissue disease; Fibrosis; Interstitial lung disease; Lung fibrosis; Systemic sclerosis scleroderma

Indexed keywords

BIOLOGICAL MARKER;

CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HUMAN; INTERSTITIAL LUNG DISEASE; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCLERODERMA; TREATMENT PLANNING; ANIMAL; COMPLICATION; DISEASE MODEL; LUNG DISEASES, INTERSTITIAL; SYSTEMIC SCLEROSIS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LUNG DISEASES, INTERSTITIAL; SCLERODERMA, SYSTEMIC;

EID: 84927725187     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000111     Document Type: Review

References (54)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66:940-944.
2. Varga J, Hinchcliff M. Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets? Nat Rev Rheumatol 2014; 10:200-202.
3. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-205.
4. Moinzadeh P, Aberer E, Ahmadi-Simab K, et al. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2014. [Epub ahead of print]
5. McCall RK, Ravenel JG, Nietert PJ, et al. Relationship of main pulmonary artery diameter to pulmonary arterial pressure in scleroderma patients with and without interstitial fibrosis. J Comput Assist Tomogr 2014; 38:163-168.
6. Mohammadi A, Oshnoei S, Ghasemi-rad M. Comparison of a new, modified lung ultrasonography technique with high-resolution CT in the diagnosis of the alveolo-interstitial syndrome of systemic scleroderma. Med Ultrason 2014; 16:27-31.
7. Rimar D, Rosner I, Nov Y, et al. Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis. Arthritis Rheumatol 2014; 66:726-730.
8. Lee CG, Herzog EL, Ahangari F, et al. Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-beta1 signaling. J Immunol 2012; 189:2635-2644.
9. Brissett M, Veraldi KL, Pilewski JM, et al. Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulinlike growth factor binding protein 3. Arthritis Rheum 2012; 64:272-280.
10. Lambrecht S, Smith V, De Wilde K, et al. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development. Arthritis Rheumatol 2014; 66:418-427.
11. Hesselstrand R, Wildt M, Bozovic G, et al. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis. Respir Med 2013; 107:1079-1086.
12. van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014; 370:433-443.
13. De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013; 40:435-446.
14. Zhang XJ, Bonner A, Hudson M, et al. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis. J Rheumatol 2013; 40:850-858.
15. Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2014; doi: 10.1136/annrheumdis-2013-204487. [Epub ahead of print] PMID:24389298.
16. Saketkoo LA, Mittoo S, Frankel S, et al. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. J Rheumatol 2014; 41:792-798.
17. De Cruz S, Ross D. Lung transplantation in patients with scleroderma. Curr Opin Rheumatol 2013; 25:714-718.
18. Lee R, Reese C, Bonner M, et al. Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 2014; 306:L736-L748.
19. Manetti M, Rosa I, Milia AF, et al. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? Ann Rheum Dis 2014; 73:1700-1709.
20. Bhattacharyya S, Kelley K, Melichian DS, et al. Toll-like receptor 4 signaling augments transforming growth factor-beta responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 2013; 182:192-205.
21. Bhattacharyya S, Tamaki Z, Wang W, et al. FibronectinEDA promotes chronic cutaneous fibrosis through toll-like receptor signaling. Sci Transl Med 2014; 6:232ra50.
22. Ohba T, McDonald JK, Silver RM, et al. Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor. Am J Respir Cell Mol Biol 1994; 10:405-412.
23. Tani K, Yasuoka S, Ogushi F, et al. Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 1991; 5:34-40.
24. Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem 2001; 276:45184-45192.
25. Atanelishvili I, Liang J, Akter T, et al. Thrombin increases lung fibroblast survival while promoting alveolar epithelial cell apoptosis via the endoplasmic reticulum stress marker, CCAAT enhancer-binding homologous protein. Am J Respir Cell Mol Biol 2014; 50:893-902.
26. Bogatkevich GS, Ludwicka-Bradley A, Nietert PJ, et al. Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis Rheum 2011; 63:1416-1425.
27. Lindahl GE, Stock CJ, Shi-Wen X, et al. Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from sclerodermaassociated interstitial lung disease. Respir Res 2013; 14:80.
28. Christmann RB, Sampaio-Barros P, Stifano G, et al. Association of interferonand transforming growth factor b-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol 2014; 66:714-725.
29. Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011; 63:783-794.
30. Assassi S, Wu M, Tan FK, et al. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum 2013; 65:2917-2927.
31. Borie R, Crestani B, Dieude P, et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS One 2013; 8:e70621.
32. Stock CJ, Sato H, Fonseca C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 2013; 68:436-441.
33. Yanaba K, Yoshizaki A, Asano Y, et al. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol 2011; 30:825-830.
34. Luzina IG, Kopach P, Lockatell V, et al. Interleukin-33 potentiates bleomycin-induced lung injury. Am J Respir Cell Mol Biol 2013; 49:999-1008.
35. Trojanowska M. Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 2009; 21:623-629.
36. Del Galdo F, Sotgia F, de Almeida CJ, et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008; 58:2854-2865.
37. Del Galdo F, Lisanti MP, Jimenez SA. Caveolin-1, transforming growth factorbeta receptor internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2008; 20:713-719.
38. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol 2003; 5:410-421.
39. Reese C, Perry B, Heywood J, et al. Caveolin-1 deficiency predisposes African-Americans to SSc-ILD. Arthritis Rheumatol 2014; 66:1909-1919.
40. Yilmaz N, Olgun S, Ahiskali R, et al. Decreased sputum caveolin-1 is associated with systemic sclerosis related lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31:55-61.
41. De Santis M, Inzitari R, Bosello SL, et al. b-Thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up. Respir Res 2011; 12:22.
42. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 2005; 11:421-429.
43. Cavasin MA, Liao TD, Yang XP, et al. Decreased endogenous levels of Ac-SDKP promote organ fibrosis. Hypertension 2007; 50:130-136.
44. Conte E, Genovese T, Gili E, et al. Thymosin b4 protects C57BL/6 mice from bleomycin-induced damage in the lung. Eur J Clin Invest 2013; 43:309-315.
45. Conte E, Iemmolo M, Fagone E, et al. Thymosin b4 reduces IL-17-producing cells and IL-17 expression, and protects lungs from damage in bleomycintreated mice. Immunobiology 2014; 219:425-431.
46. Yamaguchi Y, Takihara T, Chambers RA, et al. A Peptide derived from endostatin ameliorates organ fibrosis. Sci Transl Med 2012; 4:136ra71.
47. Ruben EC, Manuel VR, Agustin OR, et al. Ciprofloxacin utility as antifibrotic in the skin of patients with scleroderma. J Dermatol 2010; 37:323-329.
48. Bujor AM, Haines P, Padilla C, et al. Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1. Int J Mol Med 2012; 30:1473-1480.
49. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:588-594.
50. Tourkina E, Bonner M, Oates J, et al. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair 2011; 4:15.
51. Borie R, Quesnel C, Phin S, et al. Detection of alveolar fibrocytes in idiopathic pulmonary fibrosis and systemic sclerosis. PLoS One 2013; 8:e53736.
52. Manetti M, Guiducci S, Ruffo M, et al. Evidence for progressive reduction and loss of telocytes in the dermal cellular network of systemic sclerosis. J Cell Mol Med 2013; 17:482-496.
53. Manetti M, Rosa I, Messerini L, et al. A loss of telocytes accompanies fibrosis of multiple organs in systemic sclerosis. J Cell Mol Med 2014; 18:253-262.
54. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014; 343:152-157.